Barclays
COCH icon

Barclays’s Envoy Medical COCH Stock Holding History

Barclays’s Portfolio COCH Stock Details COCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-203
Closed -$157 – 5309
2025
Q3 		$157 Buy
+203
New +$275 ﹤0.01% 5253

Other funds holding COCH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
ACP
Arcus Capital Partners Atlanta, Georgia $278M AUM 14.53% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Barclays's COCH Position: Q4 2025 in Review

Barclays sold out of Envoy Medical (COCH) in Q4 2025, closing a stake of 203 shares — an estimated $157 sold.

Barclays first reported a position in COCH in Q3 2025 and held it in 1 quarter. The position peaked at $157 in Q3 2025. 27 funds tracked by Wall St. Rank hold COCH as of Q4 2025.

  • Barclays reported no remaining Envoy Medical position as of Q4 2025 after selling out during the quarter.
  • Barclays sold 203 Envoy Medical shares in Q4 2025, an estimated $157.
  • Barclays first reported a position in Envoy Medical in Q3 2025 and held it in 1 quarter.
  • Barclays's Envoy Medical position peaked at $157 in Q3 2025.
  • 27 funds tracked by Wall St. Rank held Envoy Medical as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.